Reuters: Global Markets: Vical licenses technology, vaccine booster to Bristol-Myers; shares up

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Vical licenses technology, vaccine booster to Bristol-Myers; shares up Sep 13th 2012, 20:12 Thu Sep 13, 2012 4:12pm EDT (Reuters) - Vical Inc (VICL.O) licensed its DNA immunization technology platform and its vaccine adjuvant to Bristol-Myers Squibb Co (BMY.N), sending its shares up as much as 14 percent before the bell. Under the non-exclusive, global license, Bristol-Myers will use Vical's technology to discover antibodies. Vical will also supply its product Vaxfectin, an adjuvant which has been proven to improve immune response to vaccines, to Bristol-Myers from time to time. Financial terms of the deal were not disclosed. San Diego-based Vical had cash and investments of about $97 million as of June 30, 2012. The company's shares, which have lost about 15 percent of their value this year, were up 14 percent at $4.30 in trading before the bell on Thursday.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions